Dr Robert O Gross, DO in Clear Lake, IA - General Practice

Dr Robert O Gross, DO is a General Practice physician based in Clear Lake, Iowa. Dr Robert O Gross is licensed to practice in Iowa (license number 01767) and his current practice location is 800 1st Ave N, Suite #1, Clear Lake, Iowa. He can be reached at his office (for appointments etc.) via phone at (641) 357-2141.

NPI number for Dr Robert O Gross is 1033200795 and his current mailing address is Po Box 145, Clear Lake, Iowa. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1033200795.

Contact Information

	Dr Robert O Gross, DO
	800 1st Ave N, Suite #1, Clear Lake, IA 50428-1725
	(641) 357-2141
	(641) 357-4315

Physician's Profile

Full Name	Dr Robert O Gross
Gender	Male
Speciality	General Practice
Location	800 1st Ave N, Clear Lake, Iowa
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1033200795
Provider Enumeration Date: 09/27/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Robert O Gross such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1033200795	NPI	-	NPPES
16725	Other	IA	WELLMARK

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	01767 (Iowa)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Robert O Gross is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Robert O Gross, DO Po Box 145, Clear Lake, IA 50428-0145 Ph: (641) 357-2141	Dr Robert O Gross, DO 800 1st Ave N, Suite #1, Clear Lake, IA 50428-1725 Ph: (641) 357-2141

News Archive

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

Series of regional meetings focused on ACOs are drawing healthcare leaders together: AMGA

The American Medical Group Association announced that the most recent in a series of regional meetings focused on accountable care organizations, hosted by Group Health Permanente in Seattle, Washington, continued to build on the success of previous meetings in the series. The meetings are drawing healthcare leaders together to network in an intimate setting and to learn from leading medical groups and organized systems of care that are exemplars of the ACO model.

Recurrent pregnancy loss may be caused by sperm DNA damage, finds study

Some cases of recurrent pregnancy loss may be caused by sperm DNA damage in the male partner, rather than by a problem in affected women, according to research to be presented Sunday, March 24 at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

Dr Robert O Gross, DO - General Practice in Clear Lake, IA